Comparison between conbercept and ranibizumab for treatment of neovascular age-related macular degeneratio
Not Applicable
Completed
- Conditions
- Age-related macular degenerationEye Diseases
- Registration Number
- ISRCTN86106799
- Lead Sponsor
- The First Hospital of Qiqihar City
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 180
Inclusion Criteria
1. Age 51–85 years
2. Previously untreated active neovascular AMD in one eye
3. Absence of other ocular diseases determined by examination using a tonometer, slit lamp biomicroscope and ophthalmoscope
4. Lack of polypoidal choroidal vasculopathy (PCV) as determined by indocyanine green angiography (ICGA)
5. Total area of the subretinal hemorrhage and fibrosis comprised less than 50% of the total lesion
Exclusion Criteria
1. Other serious illness
2. Systematic diseases
3. Polypoidal choroidal vasculopathy (PCV)
4. Subretinal hemorrhage and fibrosis comprised more than 50% of the total lesion
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Best-corrected visual acuity (BCVA), as determined using the ETDRS chart at one year
- Secondary Outcome Measures
Name Time Method 1. The number of injections counted at the end of one year follow-up<br>2. Retinal thickness measured at every visit by OCT<br>3. Leakage of CNV measured at every visit by fundus fluorescein angiography (FFA)<br>4. Ocular complications measured at every visit by ophthalmologist examination